- Home
- GHRS vs JANX Comparison
GHRS vs JANX Comparison
Compare GHRS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GHRS | JANX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 947.2M | 840.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GHRS | JANX |
|---|---|---|
| Price | $27.60 | $14.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $41.38 | ★ $47.00 |
| AVG Volume (30 Days) | 256.9K | ★ 1.1M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.32 | $12.12 |
| 52 Week High | $25.94 | $35.34 |
Technical Indicators
Market Signals| Indicator | GHRS | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 73.23 | 55.15 |
| Support Level | $12.88 | $13.13 |
| Resistance Level | N/A | $15.49 |
| Average True Range (ATR) | 1.72 | 0.64 |
| MACD | 0.53 | 0.12 |
| Stochastic Oscillator | 95.38 | 61.30 |
Price Performance
Historical ComparisonAbout GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.